Aribio Appoints Sung Soohyun as Co-CEO... Accelerating AR1001 Commercialization
Aribio announced on April 2 that at the shareholders' meeting held on March 31, Sung Soohyun was appointed as Co-CEO. With this, the company has officially launched a co-CEO leadership structure, with Jeong Jaejoon and Sung Soohyun jointly leading the company.
This leadership restructuring comes at a critical time, as the company prepares to conclude global Phase 3 clinical trials and announce the topline results for its oral Alzheimer’s treatment, AR1001. CEO Jeong Jaejoon will oversee research and development, global clinical trials, commercialization, and overall new drug development, while CEO Sung Soohyun will be responsible for management, business strategy, and fundraising. According to the company, the organic integration of research and management has established a more stable and robust foundation for growth.
Sung Soohyun, a co-founder of Aribio, is an executive with more than 25 years of experience in the pharmaceutical and biotech industries. Based on his people-centered management philosophy, he has worked alongside CEO Jeong Jaejoon since the company’s inception to develop therapeutics for degenerative brain diseases.
From 2010 to 2019, he served as CEO of Aribio, after which, as Vice Chairman, he led fundraising efforts and the expansion of research infrastructure. He has also contributed to the company’s entry into global markets and the establishment of a stable revenue structure.
In particular, he played a pivotal role in the development of AR1001, the oral treatment for Alzheimer’s, and spearheaded the development of the digital therapeutics for dementia, Herzion, based on accumulated research data on degenerative brain diseases. He has also been instrumental in launching functional cosmetics and health supplement businesses, including the hair loss solution Teloact.
Aribio plans to leverage CEO Sung’s expertise and business drive to successfully commercialize AR1001 and accelerate its growth into a global new drug development company.
CEO Sung stated, “I have quietly walked this path, deeply understanding the pain caused by dementia and the sorrow experienced by families. With the belief that a dream shared becomes reality, I will do my utmost to complete the final stage of developing the world’s first oral dementia treatment.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Aribio is in the process of merging with KOSDAQ-listed company Solux to strengthen its responsible management system, with the scheduled merger date set for July 10.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.